The side effects of the new drug GSK multiple myeloma, which has become increasingly bumpy in the development of daily newspapers, have been called into question.

2020.07.13 RESEARCH and DEVELOPMENT NEWS to reduce influenza risk by 86%! The preventive effect after exposure to Xofluza was significant, the new crown test kit of Sussi bio was included in the WHO emergency use list, the two drugs of Hengrui Pharmaceuticals were approved for clinical trials of the drug, and the four heavy genericdrugs of Yangzijiang were approved..We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference(click on the title, read the original text) (drug research and development) reduces the risk of influenza by 86%! The full results of the BLOCKSTONE study, which assesses family members of patients with influenza as a post-flu prophylactic measure, has been published in the New England Journal of Medicine, according to a report on the preventive effects of the post-exposure preventive effect of Yano Yi Xofluzaresults confirm that single doses of Xofluza are very effective in preventing influenza in the home environmentJunshi bio-neutral izedantibodies completed phase 1 clinical trial subjects into the group 13, Junshi Biologicals announced that the company and the Institute of Microbiology of the Chinese Academy of Sciences jointly developed a recombinant all-human anti-SARS-CoV-2 monoclonal antibody injection has recently completed the Phase 1 clinical trial in China all subjects administeredthe il-31 receptor A target blocking antibody nemolizumab 3 clinical success, Maruho announced that the evaluation of nemolizumab treatment of specific dermatitis-related itching phase III results have been published in the New England Journal of Medicineresults showed that the study reached the main efficacy endpoint: the rate of change relative to baseline screening of VAS scores in the 16th week of treatment, -42.8% in the nemolyzumab group and -21.4% in the placebo group, with statistically significant differences (p.001)" Drug Approval" Sussi bio new crown testkit included in the WHO emergency use list 13, Sussi bio issued an advertisement, the announcement shows that the company's new coronavirus 2019-nCoV nucleic acid testing kit (fluorescent PCR method) has been included in the WHO emergency use list's road to market is increasingly bumpy GSK multiple myeloma new drug side effects led the FDA to question recently, FDA staff on GlaxoSmithKline antibody drug conjugate belantamab mafodotin caused eye-related side effects, meaning the agency may not approve the drug this seasonHengrui Pharmaceuticals two drugs to obtain the drug clinical trial approval notice 13, Jiangsu Hengrui Pharmaceutical santoced that the company and subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Shengdia Biopharmaceutical Co., Ltdrecently received the Approval of the State Drug Administration issued on the injection of toluene sulfonate rymapine and SHR-1316 injections of the "Drug Clinical Trial Approval Notice."Aishi Fycompa new fine particle preparations in Japan recently announced the launch of the anti-epileptic drug Fycompa (Veketai ®, general name: perampanel, perampanay, 1%, 100 grams per bottle) new fine particle preparationsYangzijiang 4 heavy generic drugs approved on the 13th, Yangzijiang according to the new 4 categories of four generic drugs declared by the State Drug Administration approved the listing, as the same as through the consistency evaluation, delavaban tablets for the third domestic through consistency evaluation, doso-alkali injection for the second domestic through consistency evaluation, to nadoamine capsules and radon acid tofaticloth tablets are the fourth in the country through consistency evaluationEast Sunshine "Ligretin tablet" the first imitation was approved today, East Sunshine 4 generic drug Liglitin tablets approved by the State Drug Administration for listing, for the first domestic imitationcarbonate division Viram tablets domestic first imitation was approved on the 13th, Nanjing Hang Seng Pharmaceutical 4 class generic drug carbonate Sweram tablets approved by the State Drug Administration for listing, for the first imitation in Chinainto the 3rd batch of collection! Stone Pharmaceutical Group "Selaseshi bis capsule" was approved today, stone drug Oyi submitted four types of generic drug plugs to the market application obtained the approval of the State Drug Administration, as if through the consistency evaluation Nanjing Zhengda Qing "iodisaalcohol injection" approved Nanjing Zhengda Tianqing 4 class of generic drug iodized Paol injection listing application was approved by the State Drug Administration today, as the same through the consistency evaluation collection variety "Viglitin tablets" 4domestic approved 13 days of drug approval notice, Nanjing Sanhe Pharmaceutical San pharmaceutical four generic drugs "Viglitin tablets" was approved for listing, becoming the fourth domestic, and the variety also appeared in the third batch of local reporting list .